Contradictory, there is evidence suggesting that SCD1 is dispensable for de novo lipogenesis and hepatic carcinoma, whereas SCD2 was strongly upregulated during liver cancer progression [46]. This evidence concerns the gene SCD5 and hepatocellular carcinoma.